The Core of Gut Life: <i>Firmicutes</i> Profile in Patients with Relapsing-Remitting Multiple Sclerosis

The multiple sclerosis (MS) incidence rate has been increasing in Russia, but the information about the gut bacteriobiome in the MS-afflicted patients is scarce. Using the Illumina MiSeq sequencing of 16S rRNA gene amplicons, we aimed to analyze the <i>Firmicutes</i> phylum and its taxa...

Full description

Bibliographic Details
Main Authors:	Madina Kozhieva, Natalia Naumova, Tatiana Alikina, Alexey Boyko, Valentin Vlassov, Marsel R. Kabilov
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Series:	Life
Subjects:	multiple sclerosis relapsing-remitting course fecal bacteriobiome 16S rRNA gene amplicon sequencing
Online Access:	https://www.mdpi.com/2075-1729/11/1/55

Similar Items

Root and Rhizosphere Microbiome of Tomato Plants Grown in the Open Field in the South of West Siberia under Mineral Fertilization
by: Natalia Naumova, et al.
Published: (2022-11-01)

Comorbidity in in patients with relapsing-remitting multiple sclerosis
by: O.V. Somilo, et al.
Published: (2024-10-01)

Relapsing and Remitting Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Association With Infection and Vaccination: A Case Report
by: Simon Moubarak, et al.
Published: (2023-01-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
by: Flavia Salvaterra Cusin, et al.
Published: (2022-10-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

Vitamin D intoxication in a patient with relapsing-remitting multiple sclerosis – case report
by: Ioana Cociasu, et al.
Published: (2015-09-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
by: Halil Önder
Published: (2019-06-01)

Early derangement of axonal mitochondria occurs in a mouse model of progressive but not relapsing-remitting multiple sclerosis
by: Daniela Buonvicino, et al.
Published: (2023-03-01)

Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing–Remitting Multiple Sclerosis
by: Anna Bizoń, et al.
Published: (2023-08-01)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
by: Guarnera C, et al.
Published: (2017-07-01)

Fingolimod (FTY720) Tedavisinin Relapsing-Remitting Multipl Skleroz Hastalarında Karaciğer Enzim Düzeylerine Etkisi
by: Duygu Tap, et al.
Published: (2020-12-01)

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
by: Sainz de la Maza S, et al.
Published: (2023-06-01)

<i>Bacillus</i>-Based Probiotic Treatment Modified Bacteriobiome Diversity in Duck Feces
by: Natalia B. Naumova, et al.
Published: (2021-05-01)

THE EFFECT OF DEXTRANAL ON THE GUT BACTERIOBIOME OF CALVES
by: Natalia B. Naumova, et al.
Published: (2023-12-01)

Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
by: Takahiko Saida, et al.
Published: (2023-08-01)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
by: Mansour A. Alharbi, et al.
Published: (2023-05-01)

Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report
by: Marios Lemonaris, et al.
Published: (2024-01-01)

Evaluation of Diffusion Tensor Imaging Findings in Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis Patients
by: Özkan Alataş, et al.
Published: (2023-04-01)

High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trialResearch in context
by: Sandra D. Cassard, et al.
Published: (2023-05-01)

Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis
by: David Haschka, et al.
Published: (2020-04-01)

The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model
by: Gabriele Di Sante, et al.
Published: (2020-03-01)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
by: Daniel Kantor, et al.
Published: (2023-03-01)

Physical activity is related to disease severity and fatigue, but not to relapse rate in persons with relapsing remitting multiple sclerosis – a self-reported questionnaire based study
by: Marit L. Schlagheck, et al.
Published: (2023-07-01)

Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
by: Silvia Boullosa-Lale, et al.
Published: (2021-03-01)

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
by: Fianne L. P. Sips, et al.
Published: (2022-11-01)

A Special Case of Relapsing–Remitting Bilateral Encephalitis: Without Epilepsy, but Responding to Rituximab and with a Brain Biopsy Coinciding with Rasmussen Encephalitis
by: Pei Liu, et al.
Published: (2022-12-01)

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
by: Ricardo Ginestal, et al.
Published: (2023-01-01)

Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy
by: Roberto Bergamaschi, et al.
Published: (2024-06-01)

Label-free Quantitative Proteomic Analysis of Cerebrospinal Fluid and Serum in Patients With Relapse-Remitting Multiple Sclerosis
by: Haijie Liu, et al.
Published: (2022-04-01)

Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective
by: Lorenzo Giovanni Mantovani, et al.
Published: (2019-07-01)

Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta
by: Leila Karimi, et al.
Published: (2020-08-01)

Longitudinal cortex reorganization and white matter tracts structural changes analysis in relapsing-remitting multiple sclerosis patients with hand palsy
by: S. N. Kulikova, et al.
Published: (2017-02-01)

Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis
by: Masoud Ghiasian, et al.
Published: (2024-02-01)

Achievement of No Evidence of Disease Activity-3 with Oral Disease-Modifying Treatment in Patients with Relapsing–Remitting Multiple Sclerosis
by: Foziah Jabbar Gossab Alshamrani, et al.
Published: (2024-10-01)

Framework for personalized prediction of treatment response in relapsing-remitting multiple sclerosis: a replication study in independent data
by: Anna Maria Sakr, et al.
Published: (2024-06-01)

Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
by: Mohamed AlJumah, et al.
Published: (2020-02-01)

Evaluating sex hormones and cytokine profile in Egyptian females with relapsing-remitting multiple sclerosis
by: Forayssa M. Talaat, et al.
Published: (2018-11-01)

Gadolinium deposition in the brain of patients with relapsing-remitting multiple sclerosis after 10 years of follow-up
by: Kostić Dejan, et al.
Published: (2023-01-01)